Bennet, Cornyn Introduce Legislation to Lower Prescription Drug Costs and Increase Access to Biosimilars
About About Michael Legislation News Press Releases Social Media Newsletter Archive Services Priorities Top Issues Child Tax Credit Investing in Colorado Contact Español Acerca de Michael Escribe a Michael Prioridades Servicios Visitando D.C. Bennet, Cornyn Introduce Legislation to Lower Prescription Drug Costs and Increase Access to Biosimilars Washington, D.C. — Colorado U.S. Senator Michael Bennet and Senator John Cornyn (R-Texas) introduced the Increasing Access to Biosimilars Act, legislation that would direct the Department of Health and Human Services (HHS) to Create a Medicare pilot program to expand access to lower-cost alternatives to expensive biologic medicines that are as safe and effective as […] Nov 20, 2026 | Press Releases Washington, D.C. — Colorado U.S. Senator Michael Bennet and Senator John Cornyn (R-Texas) introduced the Increasing Access to Biosimilars Act, legislation that would direct the Department of Health and Human Services (HHS) to Create a Medicare pilot program to expand access to lower-cost alternatives to expensive biologic medicines that are as safe and effective as the original drugs. These medicines treat a range of serious conditions, including rheumatoid arthritis, Crohn’s disease, and certain types of cancer, such as breast cancer. “Skyrocketing prescription drug prices are causing too many Americans to have to choose between their life-saving medications and putting food on the table, especially seniors, communities of color, and the millions of people living on fixed incomes who need their prescriptions to live,” said Bennet. “This important legislation would increase patient access to lower-cost biosimilars, saving them and our health care system billions of dollars. Every American deserves affordable health care, and I look forward to working with my colleagues to move this legislation forward.” “Texas seniors should not have to break the bank to pay for their medication that’s essential to their health and well-being, yet millions are being forced to endure this financial burden because of the skyrocketing cost of prescription drugs,” said Cornyn. “I am proud to co-lead this bipartisan legislation to help ensure our seniors can afford the treatments they need by expanding access to biosimilars, which lowers drug costs for patients and alleviates the burden on Medicare beneficiaries.” Currently, providers in Medicare Part B are reimbursed for administering biologic drugs, including biosimilars, at average sales price plus +6 percent, of which the federal government pays 80 percent, and beneficiaries pay 20 percent coinsurance. This means providers are reimbursed at a higher rate for using higher-cost biologic products rather than lower-cost biosimilars. At the same time, Medicare beneficiaries are forced to pay higher copays on those brand name biologic products. This legislation would direct HHS to establish a shared savings demonstration project to increase access to biosimilars in the Medicare Part B program. Under the demonstration, Medicare would provide an additional payment to providers for using lower-cost biosimilar products, reflecting savings created in contrast to administering higher-cost reference biologic drugs. Additionally, Medicare can use a portion of those savings to reduce the beneficiary’s coinsurance payment. This would encourage physicians to prescribe less-expensive biosimilars, increasing patient access to more affordable, life-saving drugs and lowering patient out-of-pocket costs. Under the demonstration, Medicare would provide an additional payment to providers for using lower-cost biosimilar products that reflects the savings created in contrast to administering the higher-cost reference biological product. Additionally, Medicare can use a portion of those savings to reduce the beneficiary’s coinsurance payment. The Increasing Access to Biosimilar Act is supported by the Biosimilars Forum, Association for Accessible Medicines, Viatris, Biosimilars Council, and American Podiatric Medical Association. “Biosimilars are the commonsense, proven solution to America’s prescription drug affordability crisis. The Biosimilars Forum thanks Senators Bennet and Cornyn for their bipartisan leadership, and we urge Congress to pass this important bill,” said Juliana M. Reed, executive director of the Biosimilars Forum. “Biosimilars have already saved the U.S. health care system $81.6 billion, including $25.4 billion in 2025 alone. The Increasing Access to Biosimilars Act builds on that record by realigning Medicare Part B incentives so more seniors can access these lower-cost medicines. We are entering the second decade of biosimilars. The first decade proved the science. The second decade is about delivering the full promise of biosimilars. This means new products coming to market and new savings for patients, taxpayers, and the health care system.” “The Biosimilars Council and the Association for Accessible Medicines thank Senators Bennett and Corny
c54f9a9e-eb5c-4fa5-b1ee-c731fafff69eIssued within 24 hours
Other senators' releases published in the day before or after this one.